Press Releases

Adoption of the EP report “EU Pharmaceutical Strategy”

Brussels, Belgium (November 24) — The Plasma Protein Therapeutics Association (PPTA) congratulates MEP Montserrat (EPP, Spain) for the adoption of the report “EU Pharmaceutical Strategy” during the European Parliament’s Plenary session. The report was adopted by 527 MEPs on Wednesday 24 November.

Continue reading

International Plasma Awareness Week 2021: Donate Plasma. Save Lives.

ANNAPOLIS, MD (October 4, 2021) — The Plasma Protein Therapeutics Association (PPTA) is proud to mark the launch of the ninth annual International Plasma Awareness Week (IPAW), which will run from Monday, October 4 until Friday, October 8. Nearly 125,000 people in the U.S. with rare diseases, and countless others facing trauma and emergency medical needs every day, rely on medicines that are only available because of the commitment of dedicated plasma donors. Considering the nearly 20% decline in plasma donations seen last year due to the ongoing pandemic, the need for plasma donors is now more urgent than ever before. 

Continue reading

Calling on EU Policymakers to Increase Plasma Donations

Brussels, (October 4, 2021) — The Plasma Protein Therapeutics Association (PPTA) is marking the 9th annual International Plasma Awareness Week (IPAW), October 4-8, by increasing awareness and understanding about the importance of plasma, particularly the urgent need to increase plasma donations in the European Union, while also recognizing and thanking plasma donors who save and improve the lives of patients who rely on plasma for their therapies. Considering the revision of the European blood and tissues and cells legislation, PPTA calls on policymakers and regulators throughout Europe to strengthen its legal framework to benefit plasma donations for plasma-derived medicines and encourage new approaches that increase the collection of plasma across the European Union.

Continue reading


View more PPTA Press Releases


Plasma donations remain disappointingly low through ongoing pandemic, risking patients’ lives

The Plasma Protein Therapeutics Association (PPTA) is aware of emerging reports regarding patients not having reliable access to lifesaving plasma-derived therapies used to treat a variety of serious, rare, and chronic conditions caused by missing or deficient proteins in their blood. While there could be many reasons for these access challenges, the fact remains that for most of these conditions, plasma is the only starting material for effective therapies.

Continue reading

PPTA Responds to ProPublica Article

An article published by ProPublica on June 24 (“The U.S. Is Closing a Loophole That Lured Mexicans Over the Border to Donate Blood Plasma for Cash”) is the latest sensationalized reporting from ProPublica and ARD German TV reporters who continue to misrepresent and malign U.S. policies regarding plasma donation as well as the scores of committed individuals who cross the U.S.-Mexico border to donate their plasma. Tens of thousands of people safely donate their plasma every day in the U.S., with every donation directly contributing to helping nearly 125,000 Americans with serious and often life-threatening conditions live healthy and normal lives, as well as countless others facing trauma and emergency medical needs every day.

Continue reading

EU Health Commissioner says plasma donation plays a vital role

The Plasma Protein Therapeutics Association (PPTA) is proud to mark World Blood Donor Day. This day is an opportunity to specifically thank plasma donors, as well as blood donors, and recognize their shared commitment and contributions to saving and improving the lives of patients in Europe. PPTA welcomes EU Health Commissioner Kyriakides’ recognition of the crucial role of plasma and blood donors for people living with chronic and rare diseases, particularly her comment that “Blood plasma also plays a vital role with 8 million litres donated to tackle immune deficiency and make lifesaving medicines for conditions such as haemophilia, a rare condition that affects the blood's ability to clot.”

Continue reading

Study Shows Immunoglobulin Therapy is “Critical and Cost-Effective” in Treating CVID

The journal publication, “Immunoglobulin Replacement Therapy is critical and cost-effective in increasing life expectancy and quality of life in patients suffering from Common Variable Immunodeficiency Disorders (CVID): A health-economic assessment,” is authored by Professor Philippe van Wilder with the Université libre de Bruxelles and Professor Esther de Vries of Tilburg University and offers a health economic model to estimate the value of treatment with IG therapy for CVID patients.

Continue reading


View more PPTA Statements


The Source Magazine (2021-2014)

The Plasma Pool

Infusion Banner Waves1

What Does the COVID-19 Vaccine Mean for Plasma Donation?
March 2021

Continue reading

What We Know Now about the “Kawasaki-Like” Syndrome
May 2020

Continue reading



Please direct any media inquiries to

Copyright © 2020 PPTA. All rights reserved. (202) 789-3100